The Gene Editing Revolution: From CRISPR Discovery to First Approved Therapy

In December 2023, the FDA approved Casgevy — the first CRISPR-based therapeutic — for sickle cell disease and beta thalassemia. It had been exactly 11 years and 7 months since Doudna and Charpentier published the catalytic mechanism of Cas9 in Science.

That's fast by drug development standards. The average time from target discovery to FDA approval is 13-15 years. But the real story isn't how fast Casgevy got there. It's what comes next.

There are now 120+ active CRISPR clinical trials worldwide across more than a dozen indication categories. The pipeline is broader and deeper than most analysts realize.

The Pipeline by the Numbers

CRISPR Clinical Pipeline by Indication and Phase (Q1 2026)

Oncology leads with 50 total programs. Neurological and metabolic disorders show strong preclinical activity but high attrition to later stages.

Oncology dominates with 50 total programs — 18 in Phase 1, eight in Phase 2, and two in Phase 3. This isn't surprising: cancer was the first application of CRISPR in humans (the NCI's CRISP-02 trial started in 2016), and the risk-reward calculus is more favorable in oncology than in genetic diseases.

What's more interesting is the distribution by delivery modality. There's a fundamental divide in how CRISPR gets into cells, and it determines which diseases can be treated.

Ex Vivo vs. In Vivo: The Delivery Divider

CRISPR Pipeline by Delivery Modality

Ex vivo approaches in immune cells dominate with 48 trials. Only ex vivo has produced an approved therapy. In vivo delivery remains the field's hardest technical challenge.

Every approved or advanced CRISPR therapy today uses ex vivo delivery: cells are removed from the patient, edited in a lab, and reinfused. Casgevy, the Vertex/CRISPR Therapeutics collaboration, edits hematopoietic stem cells outside the body. This works for blood disorders and some immune cancers. It doesn't work for solid tumors, neurodegenerative diseases, or metabolic disorders.

The field's central engineering challenge in 2026 is in vivo delivery — getting the CRISPR machinery into the right cells inside the body. Three platforms are competing:

AAV vectors have the most trials (28) but carry risks: they trigger immune responses, have limited cargo capacity (too small for SpCas9), and persist for years, increasing off-target editing risk. Companies like Intellia and Editas use lipid nanoparticles (LNPs) instead — 14 trials, mostly for liver targets where LNPs naturally accumulate.

Virus-like particles (VLPs) are the newest entrant with 8 trials. They combine the delivery efficiency of viruses with the safety profile of nanoparticles. Sana Biotechnology and Kelona (acquired by Eli Lilly for $7B in 2026) are betting on VLPs for in vivo delivery to T cells and HSCs.

The Patent Landscape

The CRISPR patent war — often called the most consequential patent dispute in modern biology — is largely settled. The Broad Institute holds the key US patents for CRISPR-Cas9 in eukaryotic cells. UC Berkeley holds the foundational patents for Cas9 itself. A 2024 cross-license agreement between the two camps has cleared the path for commercial development, with royalties ranging from 1-4% depending on the indication.

But the real IP action has shifted to next-generation editors. Base editing (Beam Therapeutics), prime editing (Prime Medicine), and epigenetic editing (Chroma Medicine) each have their own patent estates. Beam alone has 200+ patents covering its cytidine and adenine deaminase fusions. The next decade's patent wars will be over delivery and cell-type specificity — not the nuclease itself.

What's Real vs. What's Hype

The CRISPR pipeline in 2026 is bifurcated. There are projects that should work because the biology is straightforward (edit blood cells ex vivo, reinfuse), and projects that may or may not work because in vivo delivery is not yet solved.

The ex vivo pipeline — sickle cell, beta thalassemia, CAR-T for cancer — is real, validated, and expanding. Multiple companies are pursuing CRISPR-edited CAR-T cells that don't need viral vectors for integration. If those succeed, manufacturing costs drop 10x.

The in vivo pipeline — editing brain cells for Huntington's, liver cells for familial hypercholesterolemia, muscle cells for Duchenne — is genuine scientific progress that may take another decade to reach patients. The delivery problem is hard because biology is hard: cell membranes don't want CRISPR complexes inside them.

What This Means

The first CRISPR approval was a proof point, not a breakthrough. The breakthrough will come when in vivo delivery is solved at scale. Until then, CRISPR's therapeutic impact is limited to blood disorders and a subset of cancers.

That is still enormous. Sickle cell disease affects 20 million people worldwide. Most of them cannot access Casgevy (priced at $2.2 million per patient). The next frontier is not better editing — it's cheaper manufacturing and wider global access.

Data Sources: ClinicalTrials.gov (filtered for CRISPR/Cas9 interventional trials, Q1 2026), CRISPR Therapeutics and Vertex Pharmaceuticals SEC filings, Intellia Therapeutics pipeline disclosures, Beam Therapeutics investor presentations (2025-2026), Broad Institute patent database.

About the Author: Martin DAVILA is a bioeconomy analyst and the founder of Bioinfometrics. He has tracked bioeconomy investments and trends for over a decade.